Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Yao(Central South University), Youling Gong(Sichuan University), Caicun Zhou(Tongji University), Guohua Yu(Qingdao University), Kaihua Lu(Jiangsu Province Hospital), Liyan Jiang(Southwest University), Chengping Hu(Central South University), Wei Shi(Jiangsu Hengrui Medicine (China)), Xiaoling Li(Southwest University), Quan Liu(Jiangnan University), Qiming Wang(Hunan Cancer Hospital), Xiaojing Zhang(Southwest University), Zhiyong He(Albert Einstein College of Medicine), Jun Zhao(Beijing Institute of Technology), Ben Zhang(Vanderbilt University), Ying Cheng(First Affiliated Hospital of Xi'an Jiaotong University), Runxiang Yang(Kunming Medical University), Xuhong Min(Xi'an Chest Hospital), Fei Xu(Key Laboratory of Guangdong Province), Yong Fang(Tongji Hospital), Xingya Li(Zhengzhou University), Jingxun Wu(First Affiliated Hospital of Xiamen University), Yunpeng Liu(Shenyang Institute of Automation), Lejie Cao(University of Science and Technology of China), Gongyan Chen(Harbin Medical University), Wenxiu Yao(Sichuan Cancer Hospital), Yun Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Wenhua Zhao(Shandong University), Xingxiang Xu(Northern Jiangsu People's Hospital)
The Lancet Oncology
May 13, 2022
Cited by 417


Related Papers